This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Irwin Rose | |
|---|---|
| Name | Irwin Rose |
| Birth date | July 16, 1926 |
| Birth place | Brooklyn, New York, USA |
| Death date | June 2, 2015 |
| Death place | Deerfield, Massachusetts, USA |
| Nationality | American |
| Fields | Biochemistry |
| Workplaces | University of Pennsylvania; Fox Chase Cancer Center; University of Washington; Carnegie Institution? |
| Alma mater | Columbia University; University of Chicago |
| Known for | Ubiquitin-mediated protein degradation |
| Awards | Nobel Prize in Chemistry (2004) |
Irwin Rose Irwin Rose was an American biochemist noted for elucidating the role of ubiquitin-mediated protein degradation. His work, in collaboration with Avram Hershko and Aaron Ciechanover, transformed understanding of cellular protein turnover and influenced research across cell biology, molecular biology, neurodegeneration, cancer research, and immunology. Rose's discoveries impacted drug development and biotechnology, linking fundamental enzymology to therapeutic strategies pursued by groups at institutions such as Harvard University, Massachusetts Institute of Technology, and Stanford University.
Rose was born in Brooklyn, New York City in 1926 and raised in an American Jewish household during the era of the Great Depression. He served in the United States Army near the end of World War II before pursuing higher education under the G.I. Bill. Rose studied chemistry and biochemical subjects at Columbia University and later undertook graduate work at the University of Chicago, where he was influenced by researchers working on enzymology and protein chemistry including groups affiliated with the Rockefeller University and the National Institutes of Health. During his formative years he encountered contemporary figures and institutions such as Linus Pauling, Max Perutz, John Kendrew, Erwin Chargaff, and the broader milieu of postwar American research hubs like Princeton University, Yale University, and California Institute of Technology.
Rose's postdoctoral and faculty appointments included positions at the University of Pennsylvania and the Fox Chase Cancer Center, where he collaborated with researchers studying protein degradation pathways alongside laboratories at the University of Washington, Massachusetts General Hospital, and the Salk Institute. His investigations centered on the enzymatic processes governing intracellular proteolysis and the tagging of proteins for destruction. Working in parallel with Avram Hershko at the Technion and Aaron Ciechanover at the Rabin Medical Center, Rose helped define the ATP-dependent conjugation of ubiquitin to substrate proteins, implicating enzymatic actors such as E1 ubiquitin-activating enzymes, E2 conjugating enzymes, and E3 ligases studied in labs at Cold Spring Harbor Laboratory, Max Planck Institute, and the European Molecular Biology Laboratory. The ubiquitin–proteasome pathway Rose characterized connected to research themes in Alzheimer's disease, Parkinson's disease, Huntington's disease, and cystic fibrosis, and intersected with discoveries about the proteasome complex, the 20S proteasome, and regulatory particles explored by teams at Riken, Biozentrum Basel, and Weizmann Institute of Science. Rose published with collaborators who had ties to the Howard Hughes Medical Institute, the National Science Foundation, and the American Society for Biochemistry and Molecular Biology, and his methodologies influenced structural biology efforts at European Synchrotron Radiation Facility and cryo-EM groups at University of California, San Francisco.
In 2004 Rose, along with Avram Hershko and Aaron Ciechanover, received the Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation. The award acknowledged work that reverberated across disciplines including oncology, virology, developmental biology, and cell signaling. Prior to the Nobel, Rose had been recognized by organizations such as the American Academy of Arts and Sciences, the National Academy of Sciences, and received honors congruent with prizes awarded by bodies like the Lasker Foundation and the Royal Society in recognition of seminal contributions to enzymology and cell physiology. The Nobel-winning research prompted subsequent prizes and lectureships connecting Rose to venues such as the Royal Institution, the Karolinska Institute, and keynote forums hosted by Cold Spring Harbor Laboratory and the European Molecular Biology Organization.
Rose was married and had a family; his personal life paralleled long-term commitments to teaching and mentorship at centers including University of Pennsylvania, Fox Chase Cancer Center, and research collaborations spanning Israel and the United Kingdom. His legacy endures in the widespread adoption of ubiquitin pathway inhibitors and modulators in pharmaceutical pipelines at companies like Pfizer, Novartis, Merck & Co., and biotech firms inspired by discoveries at Genentech and Amgen. Rose's influence is evident in textbooks used at Harvard Medical School, Johns Hopkins University School of Medicine, and curricula at Columbia University, where foundational concepts about protein turnover are taught. His contributions are commemorated in symposia organized by the Gordon Research Conferences, the American Chemical Society, and memorial sessions at institutions including Brandeis University and the Weizmann Institute of Science.
Category:American biochemists Category:Nobel laureates in Chemistry Category:1926 births Category:2015 deaths